Open AccessBosutinib‐associated interstitial lung disease and pleural effusion: A case report and literature review
Author(s) -
Liu Qiuying Selina,
Ass'ad Nour Ali,
Arana Yi Cecilia
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3164
Subject(s) - bosutinib , medicine , interstitial lung disease , pleural effusion , tyrosine kinase inhibitor , myeloid leukemia , lung , pathology , oncology , imatinib , nilotinib , cancer
Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom